We can’t show the full text here under this license. Use the link below to read it at the source.
Twelve‐month analysis of real‐world evidence from a telehealth obesity‐treatment provider using antiobesity medications
One-year real-world results of using weight-loss medicines through telehealth treatment
AI simplified
Abstract
In a cohort of 53,590 adults initiating antiobesity medication treatment, average weight loss reached 19.4% after 12 months.
- The population was predominantly female (88.6%) with a mean BMI of 36.9 kg/m.
- Program retention rates at 3, 6, 9, and 12 months were 78%, 63%, 58%, and 77%, respectively.
- Average weight loss was 8.9% at 3 months, 14.1% at 6 months, 17.7% at 9 months, and 19.4% at 12 months.
- GLP-1 receptor agonist-based treatments were the most commonly used medications.
- Side effects were noted to be consistent with medication classes and decreased in frequency over time.
AI simplified
Key numbers
19.4%
Average Weight Loss at 12 Months
Weight change from baseline over 12 months among participants.
77%
Retention Rate at 12 Months
Percentage of patients who maintained membership for 12 months.
29.2%
Nausea Prevalence at Treatment Initiation
Percentage of patients reporting nausea at the start of treatment.